Answers are grounded in this paper and cite their sources.
7010 Background: Mosunetuzumab (mosun) and epcoritamab (epco) are bispecific antibodies (BsAbs) approved for R/R FL, with pivotal trials (n=90-128) initially demonstrating 60-63% complete response rate (CRR), 80-82% overall response rate (ORR), and 1-year progression-free survival (PFS) rate of 58-66%. Real-world outcomes remain limited. We report the real-world efficacy and safety outcomes of BsAbs for patients (pts) with R/R FL treated in the Collaborative United States Bispecifics Consortium (CUBIC). Methods: This is a multicenter retrospective study of adult pts with R/R FL treated with standard of care mosun or epco between 2/2023 and 9/2025 at eight CUBIC centers. Efficacy outcomes included ORR, CRR, PFS, and overall survival (OS). PFS and OS were estimated using the Kaplan-Meier method. Safety outcomes included incidence and grade (G) of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Results: A total of 99 pts with R/R FL were treated with BsAb, with 92% receiving mosun (n=91) and 8% (n=8) receiving epco. Median age was 68 years (range 33-101), 61% were ≥65 years (n=60), 63% were male (n=62), 8% Hispanic (n=8), 92% (n=79) had ECOG performance status (PS) of 0-1, 51% (n=42) had FLIPI ≥3, and 31% (n=30) had elevated LDH. Median prior lines of therapy were 3 (range 1-14), and 15% (n=15) had prior CAR-T. Among 96 pts with complete response data, the ORR was 87% and CRR was 72%. Median time to best response was 2.9 months (mo) (range 1.2-12.7). Response rates were not significantly associated with BsAb, ECOG PS, FLIPI, elevated LDH, or prior CAR-T. At median follow-up of 16.9 mo, the one-yr and 18 mo PFS rates were 72% (95%CI 62-83%) and 56% (95%CI 45-70%). One-yr and 18 mo OS rates were 94% (95%CI 90-99%) and 92% (95%CI 86-99%), respectively. Hispanic pts had better PFS than non-Hispanic pts (2-yr PFS 100% vs 42%, p=0.02). PFS was not significantly influenced by BsAb product, elevated LDH, ECOG PS, FLIPI, or prior CAR-T. Patients with ECOG of 2 had inferior OS than pts with ECOG of 0-1 (2-yr OS 43% vs 89%, p=0.02). Male sex was associated with inferior OS compared to female sex (2-yr OS 76% vs 100%, p=0.02). No differences in ORR, CRR, PFS, or OS were observed between pts <65 vs ≥65 yrs or <80 vs ≥80 yrs. Of 96 pts with complete safety data, CRS occurred in 34% of pts (G1 26%; G2 6%), with no ≥G3 events. ICANS occurred in 3% of pts (n=3), all G1 events. The incidence of CRS or ICANS was not significantly associated with age, LDH, ECOG, FLIPI, or prior CAR-T. Conclusions: In this diverse, heavily pretreated real-world cohort, 61% of patients were aged ≥65 years. Bispecific antibodies for R/R FL demonstrated high response rates, favorable survival outcomes, lower rates of cytokine release syndrome—primarily due to fewer grade ≥2 events—and ICANS rates comparable to those observed in pivotal clinical trials, supporting their use across heterogeneous populations, including very elderly patients.
No takes yet. Share an insight, caveat, or question.
Allen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: